Skip to main content
Evolus, Inc. logo

Evolus, Inc. — Investor Relations & Filings

Ticker · EOLS ISIN · US30052C1071 LEI · 549300VYQRYBQOT8V419 US Manufacturing
Filings indexed 538 across all filing types
Latest filing 2024-01-16 Regulatory Filings
Country US United States of America
Listing US EOLS

About Evolus, Inc.

https://www.evolus.com/

Evolus, Inc. is a performance beauty company focused on the medical aesthetics market. The company develops and commercializes a portfolio of aesthetic products for the cash-pay sector, targeting both healthcare practitioners and consumers. Its flagship product is Jeuveau® (prabotulinumtoxinA-xvfs), a neurotoxin used for the temporary improvement of moderate to severe glabellar lines in adults. Evolus is expanding its offerings with the Evolysse™ line of hyaluronic acid-based dermal fillers, designed to correct facial wrinkles and folds. The company supports its customer-centric approach with consumer engagement platforms, including the Evolus Rewards loyalty program and the Club Evolus subscription service.

Recent filings

Filing Released Lang Actions
8-K
Regulatory Filings
2024-01-16 English
8-K
Regulatory Filings
2023-12-20 English
FORM 4
Director's Dealing
2023-12-09 English
Regulatory Filings 2023
Regulatory Filings
2023-12-06 English
SC 13G
Major Shareholding Notification
2023-11-27 English
10-Q
Interim / Quarterly Report Q3 2023
2023-11-07 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.